BackSienna Biopharmaceuticals Overview

Sienna Biopharmaceuticals Other Current Liabilities

Sienna Biopharmaceuticals's other current liabilities is $1.1M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.10M
89.30% YoYΔ $-9.22M vs prior year quarter

Peer trimmed avg / median

Loading

Sienna Biopharmaceuticals Other Current Liabilities History

Loading

Sienna Biopharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Sienna Biopharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sienna Biopharmaceuticals (SNNAQ) FAQ

Sienna Biopharmaceuticals's other current liabilities stands at $1.1M as of September 2019. That compares with $10M in the prior-year period — down 89.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Sienna Biopharmaceuticals reported $1.1M in other current liabilities versus $10M a year earlier — a 89.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $10M in the prior-year period — down 89.3% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sienna Biopharmaceuticals's other current liabilities evolved across reporting periods, while the comparison chart places SNNAQ next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Sienna Biopharmaceuticals's reading of $1.1M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.